Yazici O, Şendur MAN, Aksoy S. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J Gastroenterol 2014; 20(22): 6716-6724 [PMID: 24944464 DOI: 10.3748/wjg.v20.i22.6716]
Corresponding Author of This Article
Sercan Aksoy, MD, Department of Medical Oncology, Hacettepe University Cancer Institute, Hacettepe Mh, Sihhiye Ankara 06100, Turkey. saksoy07@yahoo.com
Research Domain of This Article
Oncology
Article-Type of This Article
Topic Highlight
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jun 14, 2014; 20(22): 6716-6724 Published online Jun 14, 2014. doi: 10.3748/wjg.v20.i22.6716
Hepatitis C virus reactivation in cancer patients in the era of targeted therapies
Ozan Yazici, Mehmet Ali Nahit Şendur, Sercan Aksoy
Ozan Yazici, Mehmet Ali Nahit Şendur, Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara 06100, Turkey
Sercan Aksoy, Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06100, Turkey
Author contributions: Yazici O wrote the manuscript and was also involved in the editing process; Şendur MAN provided articles related to the issue and was also involved in editing the manuscript; Aksoy S analyzed the reports and selected the papers that were considered relevant for the aim of this review, as well as being involved in the editing of the manuscript.
Correspondence to: Sercan Aksoy, MD, Department of Medical Oncology, Hacettepe University Cancer Institute, Hacettepe Mh, Sihhiye Ankara 06100, Turkey. saksoy07@yahoo.com
Telephone: +90-312-3052954 Fax: +90-312-3242009
Received: October 4, 2013 Revised: December 26, 2013 Accepted: March 5, 2014 Published online: June 14, 2014 Processing time: 255 Days and 2.6 Hours
Core Tip
Core tip: During treatment with targeted therapies, especially with monoclonal antibodies, viral replication is one of the major problems for cancer patients. Especially in high risk patients, such as patients with baseline chronic active hepatitis and cirrhosis, and where there are plans to administer rituximab concomitantly with corticosteroids, it is advised to have close follow-up of hepatitis C virus (HCV) viral load and to perform liver function tests. During alemtuzumab therapy we also advise to follow liver function tests and HCV RNA levels. In the course of imatinib therapy, clinicians should follow liver function alterations. Anti-human epidermal growth factor receptor 2, anti-epidermal growth factor receptor, and immunomodulating therapies can be safely used in HCV positive patients.